Structured page family:Cost guide
Teduglutide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Teduglutide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Gattex pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Teduglutide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$25,000-$35,000/month
Average wholesale price
~$23,000-$33,000/month
Pharmacy acquisition estimate
~$22,000-$30,000/month
Typical negotiated rate
~$18,000-$25,000/month
Price per dose
~$833 per 5 mg vial (0.05 mg/kg daily)
Annual cost at list price
~$300,000-$420,000
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Specialty pharmacy | $25,000-$35,000/month | REMS-required distribution |
Insurance Coverage Landscape
Commercial plans
~80-90% with SBS diagnosis and REMS
Medicare Part D
Covered as specialty
Medicaid
Most states cover with extensive documentation
VA coverage
Case-by-case
TRICARE
Case-by-case
Employer plan typical tier
Tier 5 specialty; max out-of-pocket often applies
Prior Authorization Guide
Required Documentation
- •Short bowel syndrome diagnosis
- •Parenteral nutrition dependence
- •Stable clinical status
- •REMS enrollment
- •GI specialist attestation
Common Denial Reasons
- •Insufficient SBS documentation
- •Not PN-dependent
- •REMS not completed
- •Unstable condition
Appeal Template Points
- •FDA-approved for SBS
- •PN-dependent
- •REMS enrolled
- •GI specialist managing
- •Cost offset by reduced PN costs
Expected timeline: 2-4 weeks
Savings Programs and Patient Assistance
Gattex OneSource
manufacturerEligibility: All patients
Savings: Navigation and copay support
Income limit: None
Enrollment: moderate
Takeda program coordinates insurance and PAP
Takeda PAP
manufacturerEligibility: Uninsured/underinsured
Savings: May provide at reduced or no cost
Income limit: Case-by-case
Enrollment: complex
Requires extensive documentation
Generic and Biosimilar Status
No generic currently available
Expected: No generic expected
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 0.05 mg/kg daily | $25,000-$35,000 | $300,000-$420,000 |
Annual Cost Projection
Year 1
$0-$420,000
Year 2
$0-$420,000
Year 3
$0-$420,000
Assumptions
- •Ultra-rare indication
- •PN cost offset significant
Cost-Saving Strategies
- 1.Gattex OneSource is essential for insurance navigation
- 2.Document PN volume and costs to demonstrate cost offset
- 3.REMS enrollment must be completed before dispensing
- 4.Explore foundation assistance if insurance gaps remain
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | NHS specialized commissioning | Case-by-case funding |
Need help comparing teduglutide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a teduglutide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Teduglutide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Teduglutide Cost FAQ
Sources
- 1. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.Gut • 2005Claim type: clinicalView source →
- 2. FDA Information on TeduglutideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.